Pancreatic Cancer Education
Pancreatic cancer remains one of the most challenging malignancies, but evolving combination regimens and molecular profiling are expanding treatment options. Knowledge Med sessions help community providers work through treatment decisions in interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing pancreatic cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting between FOLFIRINOX and gemcitabine-nab-paclitaxel based on patient fitness
- Incorporating molecular profiling to identify actionable targets (BRCA, NTRK, MSI-H)
- Managing biliary obstruction and other disease complications
- Integrating supportive care and nutrition management
What Sessions Cover
Knowledge Med Pancreatic Cancer sessions use interactive case simulations to address these topics and more.
- First-line therapy selection in metastatic pancreatic cancer
- BRCA-mutated pancreatic cancer: platinum-based therapy and PARP inhibitor maintenance
- Second-line options and clinical trial considerations
- Supportive oncology integration for pancreatic cancer patients
Interactive Pancreatic Cancer Sessions
Case Simulations
Work through realistic pancreatic cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Pancreatic Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Pancreatic Cancer Session
Third-party, non-promotional pancreatic cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session